News Releases

ATLANTA , April 1, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today it has taken multiple steps to focus on the health and welfare of its employees, patients, and customers.

Newest Hybrid Stent Graft Offering Enhances Ease-of-Use ATLANTA , March 4, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-vita Open NEO , a hybrid stent graft system

ATLANTA , Feb. 27, 2020 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union .  The On-X AAP

ATLANTA , Feb. 13, 2020 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Total revenues were $69.7 million in the fourth quarter of 2019, reflecting year over year growth of 3% and a 4% increase on a non-GAAP constant currency basis, both compared to the fourth quarter of 2018 On-X ®

ATLANTA , Jan. 30, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2019 fourth quarter and year-end financial results will be released on Thursday, February 13, 2020 after the market closes.  On that

Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA , Dec. 23, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S.

CryoLife Will Supply NeoPatch, a Chorioamniotic Membrane Tissue, to Misonix ATLANTA , Dec. 19, 2019 /PRNewswire/ --   CryoLife, Inc. (" CryoLife "; NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered into an agreement whereby

Product Launch Anticipated in the First Quarter 2020 ATLANTA , Dec. 2, 2019 /PRNewswire/ --   CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the E-nya thoracic stent graft system for the minimally

First Off-the-Shelf Thoraco-abdominal Stent Graft with Pre-Cannulated Inner Branch Technology ATLANTA , Dec. 2, 2019 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY),   a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside

ATLANTA , Oct. 30, 2019 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Total revenues were $67.9 million in the third quarter of 2019, reflecting year over year growth of 5% and a 6% increase on a non-GAAP constant currency basis, both compared to the third quarter of 2018 On-X ®